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Abstract The B-type Raf kinase (BRAF) V600E mutation is
a well-established biomarker for poor prognosis in metastatic
colorectal cancer (mCRC) and is a highly attractive drug
target. A barrier to the development of new therapies targeting
BRAF V600E in mCRC is the low prevalence of mutations
(approximately 10 %) and the current need for access to
sequencing-based technologies which are not routinely
available outside of large cancer centres. Availability of a
standardised immunohistochemistry (IHC) test, more suited
to routine pathology practice, would provide much broader
access to patient identification. We sought to evaluate the
accuracy and clinical utility of a recently developed BRAF
V600E IHC method as a prognostic biomarker in a large
cohort of community-based CRC patients. Archival tumour
samples from 505 patients with stage I–IV CRC were
immunohistochemically tested with two antibodies, pBR1
for total BRAF and VE1 for BRAF V600E. Cases were
assessed by two blinded pathologists, and results were com-
pared toBRAFV600Emutation status determined using DNA
sequencing. Discordant cases were retested with a BRAF
V600E SNaPshot assay. BRAFmutation status was correlated
with overall survival (OS) in stage IV CRC. By DNA se-
quencing and IHC, 505 and 477 patients were respectively
evaluable. Out of 477 patients, 56 (11. 7 %) had BRAFV600E
mutations detected by sequencing and 63 (13.2 %) by IHC.
Using DNA sequencing results as the reference, sensitivity
and specificity for IHC were 98.2 % (55/56) and 98.1 % (413/
421), respectively. IHC had a positive predictive value
(PPV) of 87.3 % (55/63) and a negative predictive
value (NPV) of 99.8 % (413/414). Compared to DNA
sequencing plus retesting of available discordant cases
by SNaPshot assay, IHC using the VE1 antibody had a
100 % sensitivity (59/59), specificity (416/416), NPV
(416/416) and PPV (59/59). Stage IV CRC patients with
BRAF V600E protein detected by IHC exhibited a
significantly shorter overall survival (hazard ratio=
2.20, 95 % CI 1.26–3.83, p=0.005), consistent with
other published series. Immunohistochemistry using the
BRAF V600E VE1 antibody is an accurate diagnostic
assay in CRC. The test provides a simple, clinically
applicable method of testing for the BRAF V600E mu-
tation in routine practice.
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Introduction
A serine/threonine kinase of the MAPK-ERK signalling path-
way, B-type Raf kinase (BRAF), and other RAF family mem-
bers are usually activated by GTP-bound RAS signalling
downstream of the epidermal growth factor receptor (EGFR)
or in response to other mitogens [1]. Mutant BRAF, however,
displays constitutive activation when affected by missense
mutation [2], most commonly V600E. Approximately 10 %
of colorectal cancers (CRCs) harbour BRAF V600E [2–4],
and this subset is associated with a significantly poorer sur-
vival [5–7] in patients with metastatic disease. BRAFmutation
may also predict lack of benefit from anti-EGFR therapy [8, 9]
in metastatic CRC, although reports are conflicting [10]. The
current clinical value of BRAF V600E detection is the delin-
eation of hereditary non-polyposis colorectal cancer
(HNPCC)-associated tumours (BRAF wild type) from spo-
radic CRCs (BRAF V600E mutant) in mismatch repair-
deficient colorectal disease [11–13] and rational patient enrol-
ment to clinical trials testing BRAF inhibitors [6].
Various methods of genotyping tumour samples for BRAF
status are currently used in diagnostic and research laborato-
ries, ranging from traditional Sanger sequencing [14] to quan-
titative pyrosequencing [15], mutation-specific real-time po-
lymerase chain reaction (RT-PCR) assays [16] and mass
spectrometry-based methods [17]. Common to all these
methods, however, is the requirement for DNA extraction
from tissue and the need for rigorous protocols to minimise
the impact of contamination of non-tumour cells on the overall
tumour to non-tumour cell ratio.
Importantly, at this point in time, the expertise and infra-
structure required for DNA-based genotyping methods are
frequently available only at academic centres and reference
laboratories. Testing for BRAFV600E therefore requires mul-
tiple steps and coordination between the primary site and
reference laboratory, resulting in sample transit costs and
diagnostic delays. Until genomic-based testing becomes avail-
able in routine community-based pathology laboratories, the
complexity involved in such testing will continue to serve as
an impediment to providing a patient’s BRAF status to their
treating clinician.
A monoclonal antibody specific to the BRAF V600E ki-
nase, VE1, has recently been described [18] and offers the
advantages of immunohistochemical determination of tumour
BRAF mutation status, no requirement for DNA purification,
low cost and the ability to perform testing on formalin-fixed
paraffin-embedded (FFPE) tissue in routine histopathology
laboratories. To date, immunohistochemistry with VE1 has
been applied to the detection of BRAF V600E in brain
metastases of varied primary sites [19], papillary thyroid
carcinoma [20, 21], Langerhans cell histiocytosis [22, 23],
ovarian carcinomas [24, 25], melanoma [26–28], lung adeno-
carcinoma [29] and hairy cell leukemia [30]. A recently pub-
lished study by Sinicrope et al. explored the VE1 antibody in a
carefully preselected group of 75 patients with stage III colo-
rectal cancer, for whom BRAF mutation status had already
been determined [31]. In another recent study examining the
utility of BRAF immunohistochemistry (IHC) in microsatel-
lite unstable CRC, Toon et al. [32] compared BRAF IHC with
conventional PCR-based molecular methods for BRAF
V600E detection in 216 patients with CRC. In a further
cohort, they also performed IHC to mismatch repair (MMR)
proteins and BRAF V600E in a larger cohort of 1,403 patients
with CRC but failed to also validate this using conventional
sequencing-based molecular techniques.
In this study, we aimed to determine the sensitivity, spec-
ificity and predictive values of VE1 immunohistochemistry
for BRAF V600E in a large community-based and unselected
cohort (n=505) of patients with CRC, with the intent of
determining how this could inform the use of this IHC-based
antibody in routine practice. FFPE tumour samples were
annotated for clinical outcomes and had been previously
assessed for BRAF status by direct (Sanger) sequencing.
Methods
Colorectal tissue samples
Primary tumour and matched normal tissue samples were
obtained from an unselected community-based cohort of 505
patients with CRC undergoing surgery at three hospitals in
Melbourne, Australia: the Royal Melbourne, Melbourne
Private and Western Hospitals. Resected tumours included
those from the proximal colon, distal colon and rectum, and
all disease stages (I–IV) were represented. This study was
approved by the ethics committees of these hospitals and the
University of Melbourne.
Tissue microarrays (TMAs) comprised of 1-mm-diameter
tissue cores were constructed from the FFPE surgical speci-
mens. Up to four tumour and two normal colon tissue cores
were embedded per patient. Tumour cores were harvested
from the areas of densest tumour cell percentage. Based on
examination of hematoxylin and eosin (H&E)-stained TMA
sections by two anatomical pathologists, cores were deemed
to contain sufficient tumour sample for immunohistochemical
analysis in 491 patients (97 %) (Fig. 1).
Sanger sequencing
All patients of the cohort were characterised for BRAF codon
600 mutation status based on Sanger sequencing at the
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Ludwig Institute Parkville, Melbourne, prior to immunohisto-
chemical analysis of TMAs. Tumours were microdissected
from the originating FFPE blocks, and the purified DNAwas
subjected to PCR and sequencing using primers and methods
previously described [6]. Samples with indeterminate se-
quencing traces on first analysis were subjected to repeat
PCR and sequencing.
Immunohistochemistry
Total BRAF and BRAFV600E-mutant proteins were detected
by immunohistochemistry using rat anti-panBRAF monoclo-
nal antibody (clone pBR1) and mouse anti-BRAF V600E
monoclonal antibody (clone VE1), respectively, both kindly
provided by Dr A. von Deimling from Ruprecht-Karls-
University, Heidelberg [18]. All assays were performed on a
BenchMark XT automated slide stainer at Ventana Medical
Systems, Inc., Tucson, AZ.
Sections from TMAs were freshly cut to 4 μm and dried at
80 °C for 15 min. The presence of total BRAF protein was
detected using ultraView Universal DAB Detection Kit
(Ventana) where ultraView Universal HRP Multimer was
substituted for an HRP-conjugated goat anti-rat secondary
antibody. The staining procedure included deparaffinisation,
pretreatment using standard Cell Conditioning 1, incubation
with pan-BRAF antibody (diluted 1:8) at 37 °C for 16min and
treatment with ultrawash.
The BRAF V600E mutation-specific IHC assay was com-
pleted with OptiView DAB IHC Detection Kit (Ventana).
Briefly, the tissue sections were deparaffinised, heat pretreated
in Cell Conditioning 1 for 64 min and followed by inactiva-
tion of the endogenous peroxidases. Specimens were
incubated with VE1 hybridoma supernatant (diluted 1:3) at
37 °C for 16 min.
Following the chromogenic detection, all slides were coun-
terstained with Hematoxylin II and Bluing Reagent (Ventana)
for 4 min each and coverslips were applied.
The immmunostained slides were evaluated independently
by two pathologists (S.S. and D.W.) blinded to the BRAF
V600E mutation status as determined by sequencing. First,
pan-BRAF IHC was assessed for the presence of total BRAF
cytoplasmic staining within invasive tumour cells. Cases were
scored as unevaluable when total BRAF expression could not
be detected, and they were excluded from further immunohis-
tochemical analysis. Next, BRAF V600E (VE1) immuno-
stained slides were evaluated for the presence or absence of
BRAF V600E protein expression. Immunoreactivity was
scored positive when there was unequivocal cytoplasmic
staining above background in the majority of invasive viable
tumour cells. Any nuclear staining, weak cytoplasmic staining
of isolated tumour cells or focal confluent staining of tumour
cells in a tumour that otherwise showed no staining was
scored as immunonegative.
SNaPShot assays
DNA was extracted with QIAamp DNA FFPE Tissue Kit
(Qiagen) from tumour cells microdissected from unstained
FFPE tissue slides and then quantitated using a Qubit® fluo-
rometer (Invitrogen, Grand Island, NY, USA). Purified tu-
mour DNA was PCR-amplified for 30 cycles at 94
and 72 °C, for 45 s each, using BRAF exon 15 forward
(TTCATAATGCTTGCTCTGATAGG) and reverse (AGTA
ACTCAGCAGCATCTCAGG) primers (GeneWorks,
Thebarton, SA, Australia) and AmpliTaq Gold® DNA
Polymerase (Applied Biosystems, Grand Island, NY, USA).
The 246-bp products were treated with ExoSAP-IT (USB) at
37 °C for 30 min and 80 °C for 15 min to remove excess
nucleotides and primers. HPLC-purified detection primer
((C)5TGATTTTGGTCTAGCTACAG) (GeneWorks) was
added to the cleaned product together with PRISM SNaPshot
Multiplex Ready Reaction Mix (Applied Biosystems) contain-
ing fluorescent ddNTPs. The detection primer was extended by
thermocyling for 35 cycles at 96 °C for 10 s, 48 °C for 1 min
and then 60 °C for 30 s. Excess nucleotides and primers were
removed by shrimp alkaline phosphatase (Sigma, St. Louis,
MO, USA) treatment at 37 °C for 1 h followed by 75 °C for
15 min, and the cleaned fragments were run in Hi-Di
Formamide (Applied Biosystems) through an ABI 3130xl ge-
netic analyser (Applied Biosystems) and analysed by
GeneMapper® fragment analysis software. A mutation was
called when the area under the fluorescent peak for the mutant
allele was greater than five times the background relative fluo-
rescent units. This method has been reported to detect mutations
in tissue samples containing ≤5 % tumour cells [33–35].
505 primary colorectal tumors
491 with adequate tumor cores
14 (2.9%) tumors with insufficient
tumor tissue in TMA cores
14 (2.9%) non-evaluable as 
pBR1 staining negative
477 evaluable by IHC
VE1 IHC Results:
63  (13.2%) VE1 positive  
414 (86.8%) VE1 negative 
477 evaluable for sensitivity, 
specificity and predictive values
Fig. 1 Workflow and results for immunohistochemistry on tissue
microarray (TMA) sections
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Statistical analyses
Sensitivity, specificity and predictive values for IHC in com-
parison to direct DNA sequencing were determined as per
convention [36, 37]. Overall survival (OS) in stage IV disease
was defined as the time from diagnosis of metastatic CRC to
death from any cause. Analyses included patients with de
novo stage IV disease and those diagnosed with distance
recurrence after prior treatment of earlier stage disease.
Survival times were estimated using the Kaplan-Meier meth-
od, and results were compared using the log-rank test.
Statistical significance was defined as p<0.05.
Results
BRAF V600E status
Using Sanger sequencing, 11.7 % (59/505) of stage I–IV CRC
patients were BRAFV600Emutation positive and the remainder
were wild-type (WT). No tumour carried non-V600E mutations
at codon 600. Of the 491 patients with adequate TMA tumour
tissue for interpretation of total BRAF (pBR1 antibody) and
BRAF V600E (VE1 antibody) immunohistochemistry, 14 pa-
tients (2.9 %) were negative for pBR1 staining and were accord-
ingly deemed unevaluable for BRAF status by IHC (Fig. 1). Of
the 477 ‘evaluable’ (pBR1 positive) patients, 63 (13.2 %) were
positive for VE1 (‘BRAF V600E’) and 414 (86.8 %) were
negative for VE1 staining (‘BRAF WT’) (Fig. 2). Of the 63
pBR1- and VE1-positive cases, the majority showed moderate
to strong homogeneous cytoplasmic staining with the VE1
antibody. Occasional cases showed uniformly weak staining or
focal patches of no staining in otherwise clearly positive tu-
mours. Of the 414 pBR1-positive and VE1-negative cases, 8
(1.9 %) showed weak patchy positivity for VE1 (Fig. 3). All
eight such heterogeneous cases were BRAFWT by sequencing.
In normal colonic mucosa, nuclear VE1 staining was frequently
observed in surface epithelial cells (Fig. 4).
The clinicopathological features and IHC results for the
evaluable patient population are shown in Table 1. A higher
frequency of BRAF V600E positivity was seen in female
patients and CRCs resected from the right colon, exhibiting
poor differentiation or with microsatellite instability (MSI).
These results are consistent with the findings of multiple prior
cohort studies typing V600 mutations using DNA-based
methods [38–40].
The sensitivity, specificity and predictive values for IHC
were determined in the evaluable population as compared to
the results from Sanger sequencing, which was considered to
be the current gold standard for the determination of BRAF
genotype. The sensitivity of VE1 staining for BRAF V600E
was 98.2 % (55/56), specificity 98.1 % (413/421), negative
predictive value (NPV) 99.8 % (413/414) and positive predic-
tive value (PPV) 87.3 % (55/63) (Table 2).
Further investigation of discordant cases
Based on the Sanger sequencing results and IHC conducted
on TMA cores, there were eight apparent IHC false-positive
cases and one apparent IHC false-negative case (Table 2,
Fig. 5). We sought to resolve these nine discordant cases by
retesting and applying additional methods to detect or exclude
BRAF V600E. To exclude the possibilities of sample mis-
matches or sampling error arising from the use of TMA cores
for IHC, whole tissue sections were cut from the original
FFPE tissue blocks and reprocessed for BRAF sequencing
and IHC. In addition, to increase the sensitivity of DNA-
based determination of BRAF mutation status, BRAF
SNaPshot assays [34, 35] were performed on DNA extracted
from tumour cells microdissected from sections adjacent to
the original tissue sections utilised.
The original archival FFPE tissue blocks could be obtained
for these further analyses from seven of the nine patients with
discordant results, comprising six IHC false-positive and the
single IHC-false negative case (Fig. 5). For three of the initial
IHC false-positive cases, reanalyses confirmed the presence of
the BRAF V600E mutation upon IHC and SNaPshot (allele
frequencies of 33, 27 and 3 %), but Sanger sequencing again
missed these mutant cases. In contrast, the other three initial
IHC false-positive cases were found to beWTupon reanalysis
with Sanger sequencing, SNaPshot and IHC on the whole
mount slides (two with 0 % and one with 10 % of cells
staining). Of the three cases erroneously VE1 positive on
TMA IHC, review of the tissue core harvest sites on the
VE1 whole sections showed sampling from heterogeneously
stained areas in two of the three cases.
The single initial IHC false-negative case was confirmed to
be BRAF V600E by resequencing and SNaPshot analysis
(mutant allele frequency of 17 %) and showed corresponding
VE1-positive staining in 47 % of tumour cells in the whole
tissue section. Most discrepancies were, therefore, due to
either low sensitivity of Sanger sequencing and/or heteroge-
neous VE1 antibody staining compounded by sampling error
from the use of TMAs. When the two discordant cases with
unavailable blocks for retesting were excluded, the VE1 anti-
body had a 100 % sensitivity, specificity, NPVand PPV in the
population of reevaluable cases (n=475) (Table 3).
Prognostic significance of VE1 positivity
We determined the prognostic significance of VE1 positivity
in patients of the evaluable cohort with de novo (n=108) or
recurrent (n=87) metastatic disease using final results after
investigation of the discordant cases with whole mount IHC
and SNaPShot assays. Survival data was available for 188
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(96 %) patients of this subgroup. The median OS with meta-
static disease for patients with BRAF V600E tumours on IHC
was 275 days compared to 518 days for those with BRAFWT.
The hazard ratio for OS with BRAFV600E was 2.20 (95% CI
1.26–3.83, p=0.005) (Fig. 6).
Discussion
Mutation of BRAF V600E is a well-validated poor prognostic
marker in metastatic CRC [5–7], as well as a discriminator
between HNPCC-related disease and sporadic MSI CRCs
Fig. 2 Representative images of
pBR1-positive tumours either
positive or negative for VE1. The
upper panels represent a BRAF
wild-type tumour, showing a
hematoxylin and eosin (H&E),
b total BRAF (pBR1) expression
and c lack of BRAF V600E
(VE1) protein. The lower panels
demonstrate a confirmed BRAF
V600E mutant tumour displaying
d H&E and e total BRAF (pBR1)
and f BRAF V600E (VE1)
protein expression
Fig. 3 Representative images demonstrating heterogeneous staining of
mutant BRAF V600E protein. a–d pan-BRAF IHC (pBR1) detects total
BRAF within all cores of a single case. e–h Using the mutation-specific
antibody VE1, mutant BRAF V600E is only present within cores f and h
and absent within cores e and g of the same case
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[11–13]. Perhaps the greatest promise of BRAF V600E detec-
tion, however, is in the application of targeted therapies in the
emerging era of personalised medicine. While BRAF-mutant
colorectal cancer has not demonstrated the same responsive-
ness to single-agent BRAF inhibitors seen in metastatic mel-
anoma [41, 42], recent research findings show encouraging
headway in the characterisation of CRC resistance mecha-
nisms [42–44]. Clinical studies combining BRAF inhibitors
with EGFR inhibitors, PI3K inhibitors or MEK inhibitors are
now underway based on these recent data and will require
accurate, efficient identification of patients with BRAF-mutant
CRC.
We report a large series of community-based colorectal
cancers screened for BRAF V600E mutation using the novel,
mutation-specific monoclonal antibody VE1. In this study,
blinded interpretation of VE1 IHC on CRC cores embedded
in TMAs showed 98.2 % sensitivity, 98.1 % specificity,
87.3 % PPV and 99.8 % NPV against BRAF genotype deter-
mined by direct sequencing. Similar sensitivities and specific-
ities for VE1 have been reported in papillary thyroid cancer,
lung cancer and melanoma [20, 27–29]. Given that positive
IHC results are likely to be verified by gene-based mutation
detection methods and accurate identification of BRAF muta-
tion is expected to facilitate access to novel targeted therapies,
the NPVof VE1 IHC is of the highest importance. Only one
sample in this study was falsely negative on VE1 TMA IHC
and subsequently shown to be clearly VE1 positive on whole-
section staining. The resolution of discordant findings for this
case, and the further six available TMA IHC false-positive
cases, by additional methods is reasonable in the context of
this particular study. It is important to note that whole-section
IHC would be conducted in routine clinical practice, rather
than via the creation of TMAs. In addition, numerous
genotyping methods have been recently demonstrated to be
more sensitive than Sanger sequencing [15–17, 27]. The
sensitivity, specificity, PPV and NPV were each recalculated
as 100 % in the fully evaluable patient population. As
Fig. 4 Representative images
of normal colon indicating a
hematoxylin and eosin (H&E),
b cytoplasmic total BRAF
expression (pBR1) and c both
cytoplasmic and nuclear staining
in normal colonic epithelium
(VE1)
Table 1 Clinical characteristics of patients with colorectal cancer
evaluable by immunohistochemistry (n=477)
Feature n (%) BRAF V600E IHC
positive, n (%)
Mean age (years) 70.5
Gender
Male 193 (40) 10 (5)
Female 282 (59) 53 (19)
Unknown 2 (<1) 0 (0)
Tumour site
Right colon 200 (42) 52 (26)
Left colon 193 (40) 8 (4)
Rectum 82 (17) 3 (4)
Unknown 2 (<1) 0 (0)
Tumour stage
I 27 (6) 2 (7)
II 148 (31) 23 (16)
III 192 (40) 23 (12)
IV 108 (23) 15 (14)
Unknown 2 (<1) 0 (0)
Differentiation
Well moderate 304 (64) 25 (8)
Poor 161 (34) 35 (22)
Unknown 12 (3) 3 (25)
Microsatellite status
Microsatellite stable 371 (78) 24 (6)
Microsatellite unstable 96 (20) 39 (41)
Unknown 10 (2) 0 (0)
Table 2 Initial determination of BRAFV600E using immunohistochem-
istry on TMA sections versus determination by Sanger sequencing
BRAF V600E results (n=477) IHC positive IHC negative
Sequencing positive 55a 1b
Sequencing negative 8c 413d
Sensitivity (a /a+b)=55/56 (98.2 %); specificity (d /d+c)=413/421
(98.1 %); negative predictive value (d/d+b)=413/414 (99.8 %); positive
predictive value (a/a+c)=55/63 (87.3 %)
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expected, clinical correlations with BRAF V600E positivity
confirmed the same patient and tumour associations in this
patient cohort seen with BRAF genotype as determined by
DNA-based mutation detection methods [38–40], further
supporting the validity of this diagnostic approach in
community-based patient cohorts. Although we restricted sur-
vival data to the subgroup of patients with metastatic disease
(either de novo stage IVor recurrent stage IV disease, n=188),
given this is the group of patients for which the presence of a
BRAF V600E mutation is a clear prognostic factor, our sur-
vival data was again consistent with that seen in other series.
In studies forerunning to those using anti-BRAF antibod-
ies, the ability to apply immunohistochemistry for the detec-
tion of mutated gene products has been recognised in the
management of gliomas. A monoclonal antibody specific for
the mutant protein IDH1R132H, important diagnostically and
prognostically [45], has been developed and applied to clinical
samples [46, 47]. Similarly, determination of BRAF mutation
status by IHC is anticipated to confer significant benefits in
the clinical setting. Unlike genotyping methods, IHC is rou-
tinely performed in all hospital histopathology departments.
The cost of reagents, equipment and labour is projected to be
lower than that of currently available sequencing methods.
Additionally, the time to results may be shorter due to the on-
site sample processing and absence of requirement for DNA
extraction. Routine profiling of all newly diagnosed CRCs for
BRAFV600E mutation may therefore now be feasible with an
inexpensive and widely available methodology. This takes on
added significance when considering BRAFV600E’s relative-
ly low population prevalence. Detection of BRAF V600E
mutation at the time of primary CRC resection and histopath-
ological analysis has the advantages of excluding underlying
477 evaluable primary tumors
421 negative for BRAF V600E
on Sanger sequencing
9 tumors with discordant results
7 with available FFPE blocks of whole tumor sections
These investigated with:
1. Repeat IHC (identical protocol) on whole tissue sections
2. Repeat DNA extraction and BRAF SNaPshot Assay
Single initial IHC False Negative:  Positive on IHC of whole tissue section
Positive on SNaPshot assay
Six initial IHC False Positives: Cases 1-3 negative and cases 4-6 positive on IHC whole sections
ie.  three IHC results changed based on whole section IHC
Cases 1-3 negative and cases 4-6 positive for BRAF V600E on SNaPshot
ie. other three sequencing  results changed based on SNaPshot 
56 positive for BRAF V600E
on Sanger sequencing
55 positive on IHC 1 negative on IHC 8 positive on IHC 413 negative on IHC
7 investigated tumors with concordant whole section IHC and SNaPshot  assay results
Fig. 5 Initial results and
subsequent investigation of
discordance between TMA IHC




Table 3 Revised determination of BRAF V600E using immunohisto-
chemistry on TMAs and/or whole mount sections versus determination
by Sanger sequencing and/or SNaPshot assay
BRAF V600E results (n=475) IHC positive IHC negative
Sequencing/SNaPshot positive 59a 0b
Sequencing/SNaPshot negative 0c 416d
Sensitivity (a /a+b)=59/59 (100 %); specificity (d /d+c)=416/416
(100 %); negative predictive value (d/d+b)=416/416 (100 %); positive






















Fig. 6 Overall survival in metastatic colorectal cancer according to
BRAF status as determined by IHC
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HNPCC in MSI CRCs [11–13], with resultant screening im-
plications [48], and prevention of lag time awaiting BRAF
mutation results in patients later diagnosed with metastatic
disease. Given that patients with metastatic BRAF-mutant
CRC have a significantly poorer prognosis, early recognition
of their BRAF status may alter clinical decisions regarding
disease observation and, in the future, administration of mo-
lecularly directed therapies.
As per the original description of VE1 IHC on clinical
samples [18], this study applied both VE1 and pBR1 primary
antibodies to all tumours. While VE1 had been selected from
2,234 hybridoma clones as the only immunoglobulin specific
for BRAF V600E on IHC, pBR1 had been chosen from pan-
BRAF clones for its demonstrated ability to bind both BRAF
wild type and BRAF V600E on IHC and Western blots [18].
The utility of positive pBR1 staining is in its confirmation of
BRAF protein expression, reducing the likelihood of false-
negative VE1 IHC findings, i.e. the presence of BRAFV600E
genotype but negative VE1 staining due to the absence of
BRAF protein expression in the tumour. In this cohort, only
14 of 491 primary CRCs (2.9%) were negative on pBR1 IHC,
suggesting that failure to express BRAF is rare in CRC and the
routine use of pBR1 concurrently with VE1 may be unneces-
sary for this tumour type. More important than concurrent
pBR1 staining may be preservation of tissue quality, as tissue
areas subject to diathermy, showing necrosis, or frozen and
then formalin-fixed have all been reported to show lower
antigenicity for VE1 [18]. The use of freshly cut tissue sec-
tions is also recommended [19]. We noted strong staining of
normal colonic surface epithelial cell nuclei for VE1, which
could be used as a positive internal control for VE1 IHC
protocols. The reason for nuclear staining with the VE1 anti-
body is unknown.
Immunohistochemistry may be an optimal method for
determining the BRAF V600E mutation status of tissue sam-
ples with low cellularity due to its single-cell-level resolution.
In contrast, for DNA-based detection methods, even micro-
dissected tissue samples contain significant proportions of
stromal cell-derived DNA, posing challenges in the detection
of diluted tumour cell-derived mutant alleles. BRAF V600E-
specific IHC has some limitations, however. Samples collect-
ed by fine-needle aspiration (FNA) may pose a challenge
because of the fixatives used. Caution is urged until the
validity of this approach in FNA samples has been adequately
investigated. Due to the heterogeneity of VE1 staining seen in
a proportion of CRCs, 1.7 % of the evaluable population in
this study, small biopsy (e.g. core biopsies) and tissue speci-
mens may be erroneously interpreted due to sampling error.
This phenomenon was documented in our patient cohort with
the initial use of TMAs for VE1 IHC; for one sample, IHC
findings were changed from positive to negative, and for three
samples, the reverse occurred when TMA IHC findings were
compared to staining on whole mount sections. Although in
our patient cohort <3% of CRCs were negative on pan-BRAF
IHC, other malignancies with low BRAF protein expression
may not be amenable to IHC testing. VE1 is highly specific
for BRAF V600E and does not detect the protein products of
other BRAF aa.600 mutations [19, 27, 28]; hence for diseases
with a higher burden of BRAF non-V600E mutations, DNA-
based genotyping or alternative monoclonal antibodies may
be indicated, particularly should these mutations demonstrate
drug sensitivity. In CRC, <4 % of BRAF mutations are non-
V600E [4, 9], and no other aa.600 mutations were detected by
sequencing in the 505 patients of this cohort. However, we
cannot exclude the possibility that a small number of patients
may have carried other non-aa.600 BRAF mutations, as DNA
sequencing was limited to the region of aa.600.
Two recently published studies exploring the VE1 antibody
in colorectal cancer have also shown a high degree of speci-
ficity and sensitivity, but included either small series [32] and/
or a highly preselected patient population [31]. However, the
consistent findings in both of these studies add considerable
weight to our findings in supporting the incorporation of the
antibody as the initial method of detection of BRAF V600E
status in patients with colorectal cancer. As opposed to the
findings of strong concordance between the VE1 IHC anti-
body and sequencing-based techniques in these two studies
and ours, another study examining VE1 IHC in colorectal
cancer was also published recently and reports low sensitivity
(71 %) and specificity (74 %) of VE1 tested on 52 FFPE CRC
samples [49]. Methodological differences in the antigen re-
trieval, staining and signal amplification protocols resulting in
poor signal intensity and background staining likely account
for this discrepancy [49]. We found that the use of OptiView
DAB IHC Detection Kit resulted in clear discrimination be-
tween background tissue and BRAF V600E-positive tumour
cell cytoplasmic staining using the VE1 antibody. In our
experience, patchy focal staining, rather than the level of
staining intensity, can lead to difficulties with interpretation,
particularly in tissue core samples. Patchy focal staining was
occasionally seen (1.7 %) in otherwise clearly negative tu-
mours and could lead to false-positive results (Fig. 3). Patchy
focal non-staining was occasionally seen in otherwise clearly
positive tumours and could lead to false-negative results.
These staining anomalies were often present in the same areas
in restained sections and did not correspond to any ana-
tomical features such as tumour nodules. Interpretive
difficulties were often resolved by examining additional
tumour areas by staining whole mount sections. In such
cases, confirmation of BRAF status should be verified
by IHC on a different specimen from that resection or
by a sensitive molecular method.
The observation that the vast majority of CRCs stained in
this study showed either homogeneously negative or positive
BRAFV600E expression argues against the clonal acquisition
of BRAF activating mutations in primary CRCs. Interestingly,
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lack of clonality for BRAF V600E expression has also been
noted in other malignancies including metastatic lesions
[19–21, 28], despite suggestions of polyclonality for BRAF
genotype in melanoma and thyroid cancer using alternative
experimental methods [50–52]. The use of mutation-specific
antibodies to address this controversial cancer biology ques-
tion is but one of their potential research applications.
Busam et al. [53] and Sahm et al. [23] utilised VE1 IHC
in co-staining experiments to further characterise BRAF
mutation-positive melanocytic lesions and Langerhans
cell histiocytosis respectively. Exploration of staining in-
tensity has also been suggested as a potentially fruitful
translational research application [54].
In conclusion, the BRAF V600E VE1 antibody is an
accurate immunohistochemical diagnostic assay in patients
with CRC and should serve as a simple method for the
detection of the BRAF V600E mutation in routine practice.
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